X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Icosapent Ethyl
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vascepa
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Details:
The study, investigating VASCEPA for patients with very high triglycerides, met its primary efficacy endpoint and showed safety profile similar to placebo. The findings are being prepared to support Edding’s dossier for seeking regulatory approval of VASCEPA in Mainland China.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mavacamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital
Deal Size: $310.0 million Upfront Cash: Undisclosed
Deal Type: Financing October 29, 2020
Details:
Proceeds will fund advancement of the Company’s global innovation mining platform and diversified portfolio of product candidates.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tafolecimab
Therapeutic Area: Cardiology/Vascular Diseases Product Name: IBI306
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Details:
Phase 1 and Phase 2 clinical study results of the recombinant fully human monoclonal antibody Tafolecimab (IBI306) were successfully presented in the 2020 European Society of Cardiology (ESC) annual conference.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
